





**SkinBioTherapeutics plc**  
("SkinBioTherapeutics" or "the Company")

#### **Directorate Change**

**14 October 2025** - the Board of Directors of SkinBioTherapeutics, (AIM: SBTX), a life science company focused on skin health, announces that Simon Hewitson, an Executive Director on the Board and Chief Operating Officer of the Group, will be stepping away from the Company on personal grounds. Recruitment for his successor has commenced. In the meantime, his duties are being managed by Stuart Ashman, CEO, and Emily Bertram, Group Finance Director.

**Martin Hunt, Chair of SkinBioTherapeutics said:***"Simon has been a good support to the business, particularly working with our divisional companies, Bio-Tec Solutions and Dermatronics. We wish him and his family well for the future."*

**-Ends-**

#### **For more information please contact:**

**SkinBioTherapeutics plc**  
Martin Hunt, Chair  
Stuart J. Ashman, CEO  
Emily Bertram, Group Finance Director

**+44 (0) 191 495 7325**

**Singer Capital Markets** (Nominated Adviser & Broker)  
Philip Davies  
Sam Butcher  
Patrick Weaver

**+44 (0) 020 7496 3000**

**Vigo Consulting (financial press)**  
Rozi Morris, Melanie Toyne-Sewell

**+44 (0) 20 7390 0230**  
[SkinBio@vigoconsulting.com](mailto:SkinBio@vigoconsulting.com)

#### **Notes to Editors**

##### **About SkinBioTherapeutics plc**

SkinBioTherapeutics is a life science company focused on skin health. The Group's proprietary platform technology, SkinBiotix<sup>®</sup>, is based upon discoveries made by the translational dermatology team at the University of Manchester.

The Group's foundation business is targeting the skin healthcare market via five pillars, the most advanced of which are cosmetic skincare (SkinBiotix) and food supplements to modulate the immune system by harnessing the gut-skin axis (AxisBiotix). The cosmetic pillar has a partnership with Croda plc and the SkinBiotix active ingredient, Zenakine<sup>™</sup> was launched in April 2025. The Group's first in-house product, AxisBiotix-Ps<sup>™</sup>, is a food supplement to address the symptoms of mild to moderate psoriasis.

The Group is also acting as a consolidator and is making acquisitions in complementary areas such as skin care and cosmetic applications, that also bring new distribution and geographical platforms, and manufacturing capabilities through which it can funnel its in-house pillar products.

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit:

[www.skinbiotherapeutics.com](http://www.skinbiotherapeutics.com).

Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BOAZZMMGNFDGKZM